U.S. FDA Issues Complete Response Letter for Baricitinib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Incyte (INCY) PT Lowered to $148 at Jefferies Following CRL
April 17, 2017 6:44 AM EDTJefferies lowered its price target on Incyte (NASDAQ: INCY) to $148.00 (from $165.00) while maintaining a Buy rating after the "surprising" CRL on Olumiant.
Analyst Brian Abrahams said while there could be many possibilities for the FDA issue their best guess is... More
